Elixinol Global (ASX:EXL) - Group CEO, Oliver Horn
Group CEO, Oliver Horn
Source: Cannabiz
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Hemp-derived CBD producer Elixinol Global (EXL) has successfully raised $8.2 million in extra working capital via a share placement
  • Under the offer, institutional and professional investors were offered over 48 million shares worth 17 cents each
  • The company has also flagged launching a share placement plan (SPP), to give shareholders a chance to pick up an additional $2 million worth of shares
  • The recent placement offered to investors will settle on November 19, while the SPP will open the following day on November 20
  • Shares in EXL remain unchanged today, priced at 18.5 cents

Elixinol Global (EXL) has successfully raised $8.2 million in extra working capital via a recent share placement.

The hemp-derived CBD producer first announced plans to raise additional equity late last week, when it entered a trading halt.

It’s since completed the placement, receiving strong support from both new and existing institutional and sophisticated investors.

Under the terms of the placement, each new share was priced at 17 cents each — an 8.1 per cent discount to the last traded price of 18.5 cents each.

Over 48 million shares will be issued in total, with the shares expected to be settled on November 19.

Along with the placement, Elixinol has announced it will also offer shareholders a chance to buy additional shares via a share placement plan (SPP).

Eligible shareholders are invited to subscribe for up to $30,000 worth of new share, worth 17 cents each, with the offer to open on November 20.

The initial aim is to raise $2 million via the SPP, however, the company may increase or scale back the offer depending on the response.

EXL Executive Director and Group CEO Oliver Horn has thanked investors for their support thus far.

“This funding will be instrumental to Elixinol as we continue to move the Company towards a cash flow positive position – we have recently made significant progress and I feel very positive about the long term prospects for the company,” he said.

Shares in EXL have ended the day unchanged, worth 18.5 cents each.

EXL by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…